Phase 1 vaccine trial for non-metastatic and at risk triple negative breast cancer patients
Dr. Justin Johnson, Ph.D. and Dr. G. Thomas Budd, M.D. will provide us with the status and progress of the phase 1 trial of an alpha-lactalbumin vaccine in patients with operable triple-negative breast cancer.
G. Thomas BuddMedical Doctor, Hematology and Medical Oncology, Cleveland Clinic
George Thomas Budd, MD, is a staff physician in the Taussig Cancer Center at Cleveland Clinic. His clinical interests include breast cancer, sarcomas and experimental therapeutics. His research interests are focused on experimental therapies, breast cancer and sarcomas.
Board-certified in internal medicine with a subspecialty in medical oncology, Dr. Budd has authored more than 175 articles, book chapters and textbooks. He is a reviewer for numerous peer-reviewed publications including Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
In addition, Dr. Budd is a fellow of the American College of Physicians and a member of the Society of Clinical Oncology and American Association for Cancer Research.
Dr. Budd received his medical degree from the University of Kansas Medical School. He completed his internship, residency, and fellowship in medical oncology at Cleveland Clinic.
Justin Johnson Program Manager, Vincent Tuohy Laboratory, Cleveland Clinic Lerner Research InstituteJustin JohnsonProgram Manager, Vincent Tuohy Laboratory, Cleveland Clinic Lerner Research Institute
Justin Johnson, PhD, is the program manager for the research group formerly under the direction of the late Vincent K. Tuohy, PhD at the Lerner Research Institute at Cleveland Clinic. Dr. Johnson worked closely with Dr. Tuohy on the design and pre-clinical testing of the alpha-lactalbumin breast cancer vaccine that is currently in a Phase I clinical trial. He is actively involved in the research and development of novel therapeutic and prevention strategies for breast and ovarian cancers.
Dr. Johnson has co-authored more than 30 scientific publications, and most recently presented the progress of the ongoing breast cancer vaccine clinical trial study at a poster session at the San Antonio Breast Cancer Symposium in December of 2022. Dr. Johnson holds four patents for his work in developing breast cancer and ovarian cancer vaccine technology. He was recognized for his contributions to the breast cancer vaccine by The University of Akron in 2020.
Dr. Johnson received his BS in Biology from The University of Akron, and completed his PhD through Cleveland State University under the mentorship of Dr. Vincent Tuohy.